Cost-effectiveness of interferon-γ release assay screening for latent tuberculosis infection treatment in Germany

Chest

Volumn 131, Issue 5, 2007, Pages 1424-1434

  Diel, Roland ^a   Nienhaus, Albert ^b   Loddenkemper, Robert ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Institution for Statutory Accident Insurance and Prevention in the Health and Welfare Services   (Germany)

^c German Central Committee Against Tuberculosis   (Germany)

Author keywords

Contact investigation; Cost effectiveness; Interferon release assay; Latent tuberculosis infection; Latent tuberculosis infection treatment; Number needed to treat; Tuberculosis

Indexed keywords

GAMMA INTERFERON; ISONIAZID;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; GERMANY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCREENING; SENSITIVITY ANALYSIS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 34248580613     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.06-2728     Document Type: Article

References (28)

1. Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003; 361:1168-1173
2. Zellweger JP, Zellweger A, Ansermet S, et al. Contact tracing using a new T-cell-based test: better correlation with tuberculosis exposure than the tuberculin skin test. Int J Tuberc Lung Dis 2005; 9:1242-1247
3. Diel R, Ernst M, Döscher G, et al. Avoiding the effect of BCG vaccination in detecting Mycobacterium tuberculosis infection with a blood test. Eur Respir J 2006; 28:16-23
4. Lee JY, Choi HJ, Park I-N, et al. Comparison of two commercial interferon-γ assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006; 28:24-30
5. Piana F, Codecasa LR, Cavallerio P, et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006; 28:31-34
6. Diel R, Nienhaus A, Lange C, et al. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J 2006; 28:35-44
7. Wrighton-Smith P, Zellweger J-P. Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J 2006; 28:45-50
8. Lungenliga Schweiz. Erkennung der Tuberkuloseinfektion mittels Bluttest (interferon-γ). Bern, Switzerland: Lungenliga Schweiz, 2005
9. National Institute for Clinical Excellence. Tuberculosis: national clinical guideline for diagnosis, management, prevention, and control. Available at: www.nice.org.uk/. Accessed October 9, 2006
10. Diel R, Nienhaus A, Lange C, et al. Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respir Res [serial online] 2006; 7:77
11. Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose. Richtlinien für die Umgebungsuntersuchungen bei Tuberkulose [Central Committee for Control of Tuberculosis. Guidelines for environmental contact tracing in tuberculosis]. Gesundheitswesen 1996; 58:657-665
12. Schaberg T, Hauer B, Loddenkemper R, et al. Latent tuberculosis infection: recommendations for preventive therapy in adults in Germany. Pneumologie 2004; 58:92-102
13. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-γ-based assay using new antigens. Am J Respir Crit Care Med 2004; 170:59-64
14. Tissot F, Zanetti G, Francioli P, et al. Influence of bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis 2005; 40:211-217
15. Diel R, Nienhaus A, Schaberg T. Cost-effectiveness of isoniazid chemoprevention in close contacts Eur Respir J 2005; 26:465-473
16. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350:2060-2079
17. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161:S221-247
18. Lungenliga Schweiz-Bundesamt für Gesundheit. Handbuch Tuberkulose. Schweiz Med Forum 2003; 3:487-491
19. Robert-Koch Institute. Die Epidemiologie der Tuberkulose in Deutschland: Jahrbuch 2004. Berlin, Germany: Robert-Koch Institute, 2005
20. Salpeter EE, Salpeter SR. Mathematical model for the epidemiology of tuberculosis, with estimates of the reproductive number and infection-delay function. Am J Epidemiol 1998; 142:398-406
21. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999; 353:444-449
22. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281:1014-1018
23. Weinstein M, Siegel J, Gold M, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276:1253-1258
24. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998; 13:716-717
25. Snyder DC, Paz EA, Mohle-Boetani JC, et al. Tuberculosis prevention in methadone maintenance clinics: effectiveness and cost-effectiveness. Am J Respir Crit Care Med 1999; 160:178-186
26. Dasgupta K, Schwartzman K, Marchand R, et al. Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations. Am J Respir Crit Care Med 2000; 162:2079-2086
27. Porco TC, Lewis B, Marseille E, et al. Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants. BMC Public Health [serial online] 2006; 6:157
28. Dasgupta K, Menzies D. Cost-effectiveness of tuberculosis control strategies among immigrants and refugees. Eur Respir J 2005; 25:1107-1116